Table 2.
Risk factor control and medication assessed at 3 and 12 months of follow-up
| Baseline | 3-month follow-up | 12-month follow-up | ||
|---|---|---|---|---|
| Asymptomatic VAO stenosis (n = 64) |
Systolic BP (mmHg) |
151.0 ± 29.3 (n = 64) |
124.5 ± 15.4 (n = 51)* |
123.4 ± 13.8 (n = 42)* |
| Diastolic BP (mmHg) |
84.6 ± 16.0 (n = 64) |
71.0 ± 10.1 (n = 51)* |
71.5 ± 8.8 (n = 42)* |
|
| Total cholesterol (mg/dl) |
171.8 ± 36.7 (n = 63) |
|
141.0 ± 34.7 (n = 49)* |
|
| LDL cholesterol (mg/dl) |
107.9 ± 29.7 (n = 59) |
|
80.7 ± 31.3 (n = 27)* |
|
| HDL cholesterol (mg/dl) |
43.3 ± 10.5 (n = 63) |
|
44.8 ± 11.7 (n = 48) |
|
| HbA1c (%)§ |
8.0 ± 2.2 (n = 30) |
|
7.0 ± 1.2 (n = 23)‡ |
|
| Number of evaluated patients |
|
55 |
45 |
|
| Antihypertensive drug (n,%) |
|
42 (76.4) |
37 (82.2) |
|
| Antiplatelet agent or oral anticoagulant (n,%) |
|
53 (96.4) |
41 (91.1) |
|
| Statin (n,%) |
|
36 (65.5) |
33 (73.3) |
|
| Symptomatic VAO stenosis (n = 73) | Systolic BP (mmHg) |
152.6 ± 22.6 (n = 73) |
123.3 ± 16.0 (n = 57)* |
125.6 ± 14.8 (n = 49)* |
| Diastolic BP (mmHg) |
82.4 ± 15.3 (n = 73) |
69.9 ± 9.7 (n = 57)* |
72.8 ± 10.6 (n = 49)* |
|
| Total cholesterol (mg/dl) |
185.8 ± 37.3 (n = 73) |
|
148.0 ± 31.7 (n = 53)* |
|
| LDL cholesterol (mg/dl) |
112.0 ± 31.2 (n = 70) |
|
81.0 ± 27.5 (n = 30)* |
|
| HDL cholesterol (mg/dl) |
44.9 ± 10.6 (n = 73) |
|
47.1 ± 17.6 (n = 52) |
|
| HbA1c (%)§ |
8.3 ± 1.7 (n = 35) |
|
7.3 ± 0.9 (n = 22)† |
|
| Number of evaluated patients |
|
59 |
51 |
|
| Antihypertensive drug (n,%) |
|
39 (66.1) |
37 (72.5) |
|
| Antiplatelet agent or oral anticoagulant (n,%) |
|
58 (98.3) |
49 (96.1) |
|
| Statin (n,%) | 45 (76.3) | 39 (76.5) |
Values denote mean ± SD or numbers with percentages in parentheses. n number of evaluated patients.
Significantly improved compared to profiles of the baseline: *p < 0.001, †p < 0.01, ‡p < 0.05.
§HbA1c was measured in patients with diabetes mellitus.
VAO vertebral artery origin.